Drug Companies Drastically Increased Lobbying Funds in Last 3 Months
Drug companies made huge increases in their spending on lobbyists last quarter, according to the Center for Responsive Politics. Its preliminary findings:
- PhRMA spent $6.3 million in Q4 2009 and $26 million for the year, an increase of 30 percent.
- Pfizer (PFE) spent $5.6 million in Q4 and $21.9 million for the year, up 80 percent.
- Eli Lilly (LLY) spent, $2.2 million in Q4 and $11.2 million in total, up 10 percent.
Assuming the Democrats fail to pull it out of the fire, $26 million seems to be a cheap price to maintain business as usual.
- Related:
- Drug Company Lobbyists Back Coakley in Race for Kennedy Senate Seat
- Allergan Sticks It to Tanning Centers: "Botax" Axed in Favor of Sun Bed Levy
- UPDATED: Merck Wants No Public Option in Healthcare Reform
- Conservatives Spread Rumor That Healthcare Reform Mandates Microchip Implants
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- What the Bosses of AZ, Novartis and Schering Didn't Say in Their Healthcare Roundtable
- Amgen, AstraZeneca and Their Lobbyists Were Lead Givers to Baucus' Warchest
- Sanofi Also Linked to FreedomWorks, Group That Urged Healthcare Town Hall Disruptions; Armey Quits DLA Piper